替比夫定预防放(化)疗后乙肝再激活临床观察

Clinical Observation of Preventing HBV Reactivation by Telbivudine

目的:了解替比夫定在治疗慢性乙型肝炎病毒(HBV)感染患者在接受放(化)疗期间出现再激活(reactivation)的有效性和安全性。方法:随机将近2年来因肿瘤接受放(化)疗期间服用替比夫定的慢性乙肝患者30例作为治疗组,将未接受替比夫定治疗的34例患者作为对照组进行对比研究。结果:治疗组未见HBV-DNA升高,而对照组则有10例升高,治疗组ALT水平明显高于对照组(P<0.01)。结论:替比夫定能有效阻止和治疗因放疗或化疗导致的乙肝再激活,未见有严重的副作用,是安全的。

Objective：To investigate effectiveness and safety of Telbivudine in preventing the reactivation of HBV. Method： 64 HBV carriers that would be treated with radiotherapy or chemotherapy were divided into two groups randomly, in one group, 30 patients treated with Telbivudine when they were treated, and the other group did not. Liver function tests and HBV DNA were observed in all the patients every week for 3 months. Result： In the Telbivudine group, HBV viru reaction was not detected, while in the controlled group, reactivity of HBV in 10 cases（29% ） were detected, and there was significant difference between the two groups（ P 〈0.01）. There were not serious adverse events during the treatment of Telbivudine. Conclusion： It is effect and safe that preventing HBV reactivation by Telbivudine in a short term.